<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39339999</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>27</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Establishment of a Reference Material in Quality Control for Use in Infectivity and Identity Assays of Recombinant COVID-19 Vaccine, in Accordance with International Standards Organization Guidance.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">967</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12090967</ELocationID><Abstract><AbstractText>The COVID-19 pandemic, caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), began in 2019. One of the strategies for pandemic control was mass vaccination. In Brazil, the recombinant COVID-19 vaccine (RCV) was produced on a large scale and offered at no charge to the population. The specifications for quality control analyses of RCV included identity and infectivity determination. To validate the results, a reference material (RM) must be analyzed in parallel with the sample vaccine. This research aimed to establish the RM for use in the identity and infectivity assay for RCV. The candidate RM was analyzed using homogeneity and stability studies. The RM was considered homogeneous for identity (cycle threshold (Ct) ≤ 25.19) and infectivity (average x- was 9.25 log<sub>10</sub> infectious units/mL). The RM was considered adequately stable for identity during the total period in all studies, being stable at -70, 5, and 22.5 °C for 380, 313, and 14 days, respectively (Ct ≤ 21.81). For infectivity, the RM was stable at -70, 5, and 22.5 °C for 380, 97, and three days, respectively. Since the property identity and infectivity values of the RM were established, the new RM could be used in quality control analysis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ajorio</LastName><ForeName>Ana Carolina Ferreira Ballestê</ForeName><Initials>ACFB</Initials><AffiliationInfo><Affiliation>Institute of Technology in Immunobiologicals, Oswaldo Cruz Foundation, Rio de Janeiro 21040-900, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chagas</LastName><ForeName>Michel Gomes</ForeName><Initials>MG</Initials><Identifier Source="ORCID">0009-0001-9003-0873</Identifier><AffiliationInfo><Affiliation>Institute of Technology in Immunobiologicals, Oswaldo Cruz Foundation, Rio de Janeiro 21040-900, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rhodes</LastName><ForeName>Vinicius Pessanha</ForeName><Initials>VP</Initials><Identifier Source="ORCID">0000-0002-1002-7456</Identifier><AffiliationInfo><Affiliation>Institute of Technology in Immunobiologicals, Oswaldo Cruz Foundation, Rio de Janeiro 21040-900, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodrigues</LastName><ForeName>Anderson Peclat</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Institute of Technology in Immunobiologicals, Oswaldo Cruz Foundation, Rio de Janeiro 21040-900, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonçalves</LastName><ForeName>Natália Pedra</ForeName><Initials>NP</Initials><AffiliationInfo><Affiliation>Institute of Technology in Immunobiologicals, Oswaldo Cruz Foundation, Rio de Janeiro 21040-900, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Godinho</LastName><ForeName>Rodrigo Maciel da Costa</ForeName><Initials>RMDC</Initials><AffiliationInfo><Affiliation>Institute of Technology in Immunobiologicals, Oswaldo Cruz Foundation, Rio de Janeiro 21040-900, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forsythe</LastName><ForeName>Stephen James</ForeName><Initials>SJ</Initials><Identifier Source="ORCID">0000-0002-6709-0712</Identifier><AffiliationInfo><Affiliation>Foodmicrobe.com Ltd., Adams Hill, Keyworth, Nottingham NG12 5GY, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>da Costa</LastName><ForeName>Luciana Veloso</ForeName><Initials>LV</Initials><Identifier Source="ORCID">0000-0003-1873-4056</Identifier><AffiliationInfo><Affiliation>Institute of Technology in Immunobiologicals, Oswaldo Cruz Foundation, Rio de Janeiro 21040-900, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brandão</LastName><ForeName>Marcelo Luiz Lima</ForeName><Initials>MLL</Initials><Identifier Source="ORCID">0000-0003-1121-7312</Identifier><AffiliationInfo><Affiliation>Institute of Technology in Immunobiologicals, Oswaldo Cruz Foundation, Rio de Janeiro 21040-900, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">identity assay</Keyword><Keyword MajorTopicYN="N">infectivity assay</Keyword><Keyword MajorTopicYN="N">internal control</Keyword><Keyword MajorTopicYN="N">pharmaceutical industry</Keyword><Keyword MajorTopicYN="N">qPCR</Keyword><Keyword MajorTopicYN="N">quality control</Keyword><Keyword MajorTopicYN="N">recombinant COVID-19 vaccine</Keyword><Keyword MajorTopicYN="N">reference material</Keyword></KeywordList><CoiStatement>Author Stephen James Forsythe is the maintainer of Foodmicrobe.com Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39339999</ArticleId><ArticleId IdType="pmc">PMC11435733</ArticleId><ArticleId IdType="doi">10.3390/vaccines12090967</ArticleId><ArticleId IdType="pii">vaccines12090967</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Castro M.C., Kim S., Barberia L., Ribeiro A.F., Gurzenda S., Ribeiro K.B., Abbott E., Blossom J., Rache B., Singer B.H. Spatiotemporal pattern of COVID-19 spread in Brazil. Science. 2021;372:821–826. doi: 10.1126/science.abh1558.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abh1558</ArticleId><ArticleId IdType="pubmed">33853971</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  Brazil. Statistics. The Current COVID-19 Situation.  [(accessed on 19 January 2024)].  Available online:  https://www.who.int/countries/bra.</Citation></Reference><Reference><Citation>Sreepadmanabh M., Sahu A.K., Chande A. COVID-19: Advances in diagnostic tools, treatment strategies, and vaccine development. J. Biosci. 2020;45:148. doi: 10.1007/s12038-020-00114-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12038-020-00114-6</ArticleId><ArticleId IdType="pmc">PMC7683586</ArticleId><ArticleId IdType="pubmed">33410425</ArticleId></ArticleIdList></Reference><Reference><Citation>Domingues C.M.A.S., Maranhão A.G.K., Teixeira A.M., Fantinato F.F.S., Domingues R.A.S. The Brazilian National Immunization Program: 46 years of achievements and challenges. Cad. Saude Publica. 2020;36:e00222919. doi: 10.1590/0102-311x00222919.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/0102-311x00222919</ArticleId><ArticleId IdType="pubmed">33111749</ArticleId></ArticleIdList></Reference><Reference><Citation>Castro M.C., Massuda A., Almeida G., Menezes-Filho N.A., Andrade M.V., de Souza Noronha K.V.M., Rocha R., Macinko J., Hone T., Tasca R., et al. Brazil’s unified health system: The first 30 years and prospects for the future. Lancet. 2019;394:345–356. doi: 10.1016/S0140-6736(19)31243-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)31243-7</ArticleId><ArticleId IdType="pubmed">31303318</ArticleId></ArticleIdList></Reference><Reference><Citation>Dantas S.I., Amaral L.F.G., da Costa J.C.S. Technological order and technology transfer of the vaccine for COVID-19 in Brazil: A case study of the model used by AstraZeneca/Oxford and Fiocruz. Vigil. Sanit. Debate. 2022;10:57–68. doi: 10.22239/2317-269x.02068.</Citation><ArticleIdList><ArticleId IdType="doi">10.22239/2317-269x.02068</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  COVID-19 Vaccine Explainer. COVID-19 Vaccine ChAdOx1-S [Recombinant]—Developed by Oxford University and Astra Zeneca. 2021.  [(accessed on 19 January 2024)].  Available online:  https://www.who.int/publications/m/item/chadox1-s-recombinant-covid-19-vaccine.</Citation></Reference><Reference><Citation>World Health Organization . WHO Team: Health Product Policy and Standards, Technical Standards and Specifications. World Health Organization; Geneva, Switzerland: 2016. WHO good manufacturing practices for biological products. (WHO Technical Report Series, No. 999, Annex 2).</Citation></Reference><Reference><Citation>Reference Materials—Selected Terms and Definitions. 3rd ed. International Standards Organization; Geneva, Switzerland: 2017. 8p</Citation></Reference><Reference><Citation>Ajorio A.C.F.B., Rhodes V.P., Rodrigues A.P., Diniz V.A., Mattoso J.M.V., da Silva I.B., D’aiuto D., Brandão M.L.L. Evaluation of hydrogen peroxide efficacy against AZD1222 chimpanzee adenovirus strain in the recombinant COVID-19 vaccine for application in cleaning validation in a pharmaceutical manufacturing industry. Lett. Appl. Microbiol. 2022;74:536–542. doi: 10.1111/lam.13635.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/lam.13635</ArticleId><ArticleId IdType="pubmed">34921425</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson M., Ellison S.L.R., Wood R. The International Harmonized Protocol for the Proficiency Testing of Analytical Chemistry Laboratories. Pure Appl. Chem. 2006;78:145–196. doi: 10.1351/pac200678010145.</Citation><ArticleIdList><ArticleId IdType="doi">10.1351/pac200678010145</ArticleId></ArticleIdList></Reference><Reference><Citation>Ajorio A.C.F.B., Rhodes V.P., Rodrigues A.P., Diniz V.A., da Conceição G.M.S., Forsythe S.J., da Silva I.B., Brandão M.L.L. Establishment of certified reference material for the infectivity assay in yellow fever vaccine quality control, in accordance with International Standards Organization guidance. J. Pharm. Biomed. Anal. 2023;230:115395. doi: 10.1016/j.jpba.2023.115395.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpba.2023.115395</ArticleId><ArticleId IdType="pubmed">37079931</ArticleId></ArticleIdList></Reference><Reference><Citation>Reference Materials—Guidance for Characterization and Assessment of Homogeneity and Stability. 4th ed. International Standards Organization; Geneva, Switzerland: 2017. 105p</Citation></Reference><Reference><Citation>World Health Organization; Geneva, Switzerland: 2011. Manual for the Establishment of the National and Other Secondary Standard for Vaccines.</Citation></Reference><Reference><Citation>Ferguson M., Heath A. Collaborative study to assess the suitability of a candidate International Standard for yellow fever vaccine. Biologicals. 2004;32:195–205. doi: 10.1016/j.biologicals.2004.09.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biologicals.2004.09.003</ArticleId><ArticleId IdType="pubmed">15572101</ArticleId></ArticleIdList></Reference><Reference><Citation>General Requirements for the Competence of Reference Material Producers. 1st ed. International Standards Organization; Geneva, Switzerland: 2016. 24p</Citation></Reference><Reference><Citation>Singh K.A., Rai R., Nair S.S. Review on development of assigned value microbiological reference materials used in food testing. Food Microbiol. 2022;102:103904. doi: 10.1016/j.fm.2021.103904.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.fm.2021.103904</ArticleId><ArticleId IdType="pubmed">34809936</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelmassih M., Planchon V., Anceau C., Mahillon J. Development and validation of stable reference materials for food microbiology using Bacillus cereus and Clostridium perfringens spores. J. Appl. Microbiol. 2011;110:1524–1530. doi: 10.1111/j.1365-2672.2011.05007.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2672.2011.05007.x</ArticleId><ArticleId IdType="pubmed">21435123</ArticleId></ArticleIdList></Reference><Reference><Citation>Kempster S.L., Dougall T., Morris C., Gonzalez-Escobar G., Almond N., Anderson R. Utility of reference materials for Zika Virus nucleic acid testing. Biologicals. 2019;61:55–60. doi: 10.1016/j.biologicals.2019.06.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biologicals.2019.06.007</ArticleId><ArticleId IdType="pubmed">31277902</ArticleId></ArticleIdList></Reference><Reference><Citation>Penaud-Budloo M., Broucque F., Harrouet K., Bouzelha M., Saleun S., Douthe S., D’costa S., Ogram S., Adjali O., Blouin V., et al. Stability of the adeno-associated virus 8 reference standard material. Gene Ther. 2019;26:211–215. doi: 10.1038/s41434-019-0072-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41434-019-0072-9</ArticleId><ArticleId IdType="pubmed">30926961</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayuso E., Blouin V., Lock M., McGorray S., Leon X., Alvira M.R., Auricchio A., Bucher S., Chtarto A., Clark K.R., et al. Manufacturing and characterization of a recombinant adeno-associated virus type 8 reference standard material. Hum. Gene Ther. 2014;25:977–987. doi: 10.1089/hum.2014.057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/hum.2014.057</ArticleId><ArticleId IdType="pmc">PMC4236062</ArticleId><ArticleId IdType="pubmed">25275822</ArticleId></ArticleIdList></Reference><Reference><Citation>Perraut R., Girault G., Moreau J.P. Stability-related studies on 17D yellow fever vaccine. Microbes Infect. 2000;2:33–38. doi: 10.1016/S1286-4579(00)00288-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1286-4579(00)00288-4</ArticleId><ArticleId IdType="pubmed">10717538</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosas C.O., Rodrigues J.M., de La Cruz M.H.C., Lopes S.M.R., Souto A.S.S., Brandão M.L.L., Capasso I.R.V.d.F. Microbiological reference material (bacterial and fungal domains): Definition, production rules, use and need for establishment in Brazil. Braz. J. Food Technol. 2019;22:e2017208. doi: 10.1590/1981-6723.20817.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/1981-6723.20817</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>